Table 1
Azithromycin for ocular toxoplasmosis
| Patient No, sex, age (years) | Indication for treatment | Interval between onset and azithromycine medication (weeks) | Size of retinal lesion (DD) | Duration of retinitis (weeks) | Complications | Additional treatment | Visual acuity | Follow up (months) | Retinitis recurrence (follow up, months) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systemic | Ocular |
Onset | Final | ||||||||||||||||
| 1, M, 25 | patient’s choice | <1 | 1 | 3 | — | increase of vitreous opacities | pyrimethamine and prednisone | 20/50 | 20/20 | 21 | — | ||||||||
| 2, M, 44 | patient’s choice | 2 | 2.5 | 6 | — | increase of vitreous opacities | pyrimethamine and prednisone | 20/60 | 20/20 | 20 | + (5) | ||||||||
| 3, F, 24 | patient’s choice | <1 | 1 | 4 | — | — | — | 20/30 | 20/25 | 22 | + (6) | ||||||||
| 4, M, 43 | patient’s choice | <1 | 3 | 8 | — | increase of vitreous opalcities | pyrimethamine and sulphadiazine | 20/60 | 20/20 | 20 | — | ||||||||
| 5, F, 33 | patient’s choice | <1 | 1 | 3 | — | — | — | 20/30 | 20/20 | 20 | — | ||||||||
| 6, M, 28 | intolerant to triple treatment | 5 | 0.5 | 4 | — | — | prednisone | 20/200 | 20/25 | 21 | — | ||||||||
| 7, F, 31 | progressive disease with triple treatment | >8 | 6 | 7 | — | — | — | LP | LP | 20 | — | ||||||||
| 8, F, 29 | progressive disease with triple treatment | >8 | 4 | 3 | — | — | — | CF | 20/200 | 21 | — | ||||||||
| 9, M, 54 | progressive disease with triple treatment | 8 | 2 | 4 | — | — | — | 20/60 | 20/25 | 23 | — | ||||||||
| 10, F, 73 | intolerant to triple treatment | 3 | 3 | 5 | — | — | — | HM | HM | 20 | + (7) | ||||||||
| 11, F, 69 | intolerant to triple treatment | 2 | 1.5 | 4 | — | — | — | CF | 20/50 | 13 | — | ||||||||
